EW
Edwards Lifesciences Corporation
NYSE · USHealthcareMedical - Devices
$85.00-0.85%
Price as of Jul 20, 2026
EW financials
Edwards Lifesciences Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $6.1B | $5.4B | $5.0B | $5.4B |
| Cost of revenue | $1.3B | $1.1B | $1.0B | $1.2B |
| Gross profit | $4.7B | $4.3B | $4.0B | $4.2B |
| Operating expenses | $3.1B | $2.9B | $2.5B | $2.5B |
| Operating income | $1.6B | $1.4B | $1.4B | $1.7B |
| Net income | $1.1B | $4.2B | $1.4B | $1.5B |
| EBITDA | $1.4B | $1.7B | $1.5B | $2.0B |
| Basic EPS | $1.84 | $6.98 | $2.31 | $2.46 |
| Diluted EPS | $1.83 | $6.97 | $2.30 | $2.44 |
| Balance sheet | ||||
| Cash & equivalents | $2.9B | $3.0B | $1.1B | $769.0M |
| Total assets | $13.7B | $13.1B | $9.4B | $8.3B |
| Total liabilities | $3.4B | $3.0B | $2.6B | $2.5B |
| Stockholders’ equity | $10.3B | $10.0B | $6.7B | $5.8B |
| Total debt | $705.4M | $700.0M | $685.1M | $691.3M |
| Net debt | -$2.2B | -$2.3B | -$447.2M | -$77.7M |
| Cash flow | ||||
| Operating cash flow | $1.6B | $542.3M | $895.8M | $1.2B |
| Capital expenditure | -$260.2M | -$252.4M | -$266.3M | -$264.8M |
| Free cash flow | $1.3B | $289.9M | $629.5M | $953.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$893.4M | -$1.2B | -$879.6M | -$1.7B |